PAT 409

Drug Profile

PAT 409

Alternative Names: PAT-409

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmAkea Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Skin disorder therapies
  • Mechanism of Action ENPP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cholangitis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Kidney disorders; Non-alcoholic steatohepatitis; Scleroderma

Most Recent Events

  • 20 Nov 2017 Preclinical trials in Inflammatory bowel disease in USA before November 2017 (PharmAkea Therapeutics pipeline, November 2017)
  • 20 Oct 2017 Pharmacodynamics data from a preclinical trial in non-alcoholic steatohepatitis presented at the The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 22 Aug 2017 Preclinical trials in Cholangitis in USA before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top